French National Registry of Bone Marrow Failures (RIME)

• ClinicalTrials.gov Identifier: NCT04781790
• Recruitment Status: Recruiting
• First Posted: March 4, 2021
• Last Update Posted: March 4, 2021
• Sponsor: Assistance Publique - Hôpitaux de Paris
• Information provided by (Responsible Party): Assistance Publique - Hôpitaux de Paris

Study Description

Brief Summary:

This is a unique clinical and biological database that collects standardized clinical information during the management of all patients with bone marrow failure syndromes (BMF) in France (multicenter registry), from diagnosis and throughout follow-up during the natural history of the disease, treated or not. In parallel, biological samples (blood and/or bone marrow and/or skin) are collected during clinical care and are biobanked in Saint-Louis Hospital (Hematology laboratory) in order to be used in translational research related to bone marrow failure diseases.

This registry has two main objectives:

• Public health care evaluation and improvement: to assess the medical and social needs inherent to the management of these rare diseases; to precisely assess the level of diagnosis and management of bone marrow failure syndromes in France; to evaluate the impact and guidance of the French reference center guidelines for diagnosis and treatment; to evaluate the real-life efficacy and tolerance of any given specific treatments; to analyze treatment's cost-effectiveness according to each situation.

• Research:

  • Epidemiology: to determine the incidence, prevalence, and distribution of different bone marrow failure syndromes at the national level;
  • Biology: to better understand the pathophysiology of BMF; to identify and to study complications within each entity, such as mechanisms underlying clonal evolution, new forms of inherited BMF and acute myeloid leukemia (AML)/MDS-predisposition syndromes, and to better and deeper characterize known entities;
  • Treatment: to identify prognostic factors and predictors of response; to identify side effects and impact of treatment on others organs and natural functions; to assess patients' quality of life as early as possible since diagnosis and throughout follow-up.

Condition or disease	Intervention/treatment
Bone Marrow Failure Syndrome	Other: Bone Marrow Failure

Study Design

• Study Type: Observational
• Estimated Enrollment: 5000 participants
• Observational Model: Other
• Time Perspective: Prospective
• Official Title: French National Registry of Bone Marrow Failures: Prospective and Retrospective Database Associated to a Collection of Biological Samples: RIME Project
• Actual Study Start Date: February 6, 2017
• Estimated Primary Completion Date: February 6, 2027
• Estimated Study Completion Date: February 6, 2027

Groups and Cohorts

Group/Cohort	Intervention/treatment
Patients with Bone marrow failure; Standard of care of patients with bone marrow failure	Other: Bone Marrow Failure; without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.

Outcome Measures

Primary Outcome Measures :

1. Prevalence of bone marrow failure [ Time Frame: at 10 years ]
2. Distribution of different bone marrow failure syndromes [ Time Frame: at 10 years ]

Secondary Outcome Measures :

1. Quality of life assessed by EORTC QLQ-C30- v3 questionnaire [ Time Frame: at inclusion ]

   Quality of life evaluated using questionnaire "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire" (EORTC QLQ-C30- v3). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/ QoL represents a high QoL and a high score for a symptom scale/item represents a high level of symptomatology/problems.

   EORTC QLQ-C30 Scoring Manual. Fayers PM et al. on behalf of the EORTC Quality of Life Group. EORTC, 2001. ISBN: 2-9300.

2. Quality of life assessed by EORTC QLQ-C30- v3 questionnaire [ Time Frame: at 10 years ]

   Quality of life evaluated using questionnaire "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire" (EORTC QLQ-C30- v3). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/ QoL represents a high QoL and a high score for a symptom scale/item represents a high level of symptomatology/problems.

   EORTC QLQ-C30 Scoring Manual. Fayers PM et al. on behalf of the EORTC Quality of Life Group. EORTC, 2001. ISBN: 2-9300.

3. mechanisms underlying a clonal evolution or AML/MDS syndroms [ Time Frame: at 10 years ]
4. Proportion of patients with new forms of constitutional aplasias [ Time Frame: at 10 years ]
5. Proportion of patients with complications within each entity [ Time Frame: at 10 years ]
6. Prognostic factor ans treatment response [ Time Frame: at 10 years ]
7. Pathophysiology of bone marrow failures [ Time Frame: at 10 years ]
8. Global response to treatment [ Time Frame: at 10 years ]
9. Incidence and outcome of extra hematological complications including solid tumors, fertility [ Time Frame: within 10 years ]

Biospecimen Retention:   Samples With DNA

Laboratory of hematology, Saint Louis hospital, Paris, France (blood, bone marrow, skin)

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Patients with bone marrow failure syndromes (BMF)

Criteria

Inclusion Criteria:

• All age
• All diagnostic of BMF
• Having given his non-opposition to registry after understand overall aims
• Having signed a written informed consent (2 parents for patients aged less than 18) for collection of biological samples
• With health insurance coverage

Exclusion Criteria:

With myelodysplastic syndrome occurring in a patient over the age of 50 in absence of genetical predispositions, familial forms and history of medullary hypoplasia

Contacts and Locations

Contacts

Contact: Régis Peffault De Latour; +33142385073; regis.peffaultdelatour@aphp.fr

Contact: Matthieu Resche-Rigon; +3341499742; matthieu.resche-rigon@u-paris.fr

Locations

France

Hématologie Greffe; Recruiting

Paris, France

Contact: Regis PEFFAULT DE LATOUR

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

More Information

• Responsible Party: Assistance Publique - Hôpitaux de Paris
• ClinicalTrials.gov Identifier: NCT04781790
• Other Study ID Numbers: NI17045J
• First Posted: March 4, 2021
• Last Update Posted: March 4, 2021
• Last Verified: February 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Assistance Publique - Hôpitaux de Paris:

aplastic anemia; Fanconi anemia; blackfan diamond anemia; telomeropathies; inherited aplastic anemia; acquired aplastic anemia; medullary hypoplasia

Additional relevant MeSH terms:

Bone Marrow Failure Disorders; Pancytopenia; Bone Marrow Diseases; Hematologic Diseases